These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 15510237)

  • 1. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia.
    Rabasseda X
    Drugs Today (Barc); 2004 Aug; 40(8):649-61. PubMed ID: 15510237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
    Djavan B; Milani S; Fong YK
    Expert Opin Pharmacother; 2005 Feb; 6(2):311-7. PubMed ID: 15757426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Nickel JC; Hoefner K; Andriole G;
    Urology; 2002 Sep; 60(3):434-41. PubMed ID: 12350480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
    BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
    Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
    Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
    J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.
    Andriole GL; Kirby R
    Eur Urol; 2003 Jul; 44(1):82-8. PubMed ID: 12814679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
    J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5 alpha-reductase inhibitors: what's new?
    Foley CL; Kirby RS
    Curr Opin Urol; 2003 Jan; 13(1):31-7. PubMed ID: 12490813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5α-reductase type 1 modulates insulin sensitivity in men.
    Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dutasteride: a review of its use in the management of prostate disorders.
    Keam SJ; Scott LJ
    Drugs; 2008; 68(4):463-85. PubMed ID: 18318566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.